Amifostine is a potent radioprotector of salivary glands in radioiodine therapy. Structural and ultrastructural findings.
Standard
Amifostine is a potent radioprotector of salivary glands in radioiodine therapy. Structural and ultrastructural findings. / Kutta, Hannes; Kampen, Uwe; Sagowski, Christoph; Brenner, Winfried; Bohuslavizki, Karl-Heinz; Paulsen, Friedrich.
In: STRAHLENTHER ONKOL, Vol. 181, No. 4, 4, 2005, p. 237-245.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Amifostine is a potent radioprotector of salivary glands in radioiodine therapy. Structural and ultrastructural findings.
AU - Kutta, Hannes
AU - Kampen, Uwe
AU - Sagowski, Christoph
AU - Brenner, Winfried
AU - Bohuslavizki, Karl-Heinz
AU - Paulsen, Friedrich
PY - 2005
Y1 - 2005
N2 - BACKGROUND AND PURPOSE: Salivary gland impairment following high-dose radioiodine treatment is well recognized. Since differentiated thyroid cancer has a good prognosis, reduction of long-term side effects is important. This study investigates the radioprotective effects of amifostine in salivary glands of rabbits receiving high-dose radioiodine therapy so as to obtain deeper insight in changes on the cellular and ultrastructural level. MATERIAL AND METHODS: A total of 20 rabbits were investigated. High-dose radioiodine therapy applying 1 GBq (131)I was performed in 16 animals. Eight of these 16 animals received 200 mg/m(2) body surface amifostine prior to high-dose radioiodine therapy. Four additional rabbits served as controls, two receiving amifostine, the other two no treatment at all. Subsequently, salivary glands (submandibular and parotid glands, respectively) of all animals were examined by light and transmission electron microscopy. RESULTS: Parenchymal damage of both parotid and submandibular glands, specially acinar structures comprising cell organelles and nuclei, of animals pretreated with amifostine was much less pronounced than in animals without amifostine pretreatment. CONCLUSION: The results indicate that parenchymal damage in salivary glands induced by high-dose radioiodine therapy can significantly be reduced by amifostine. Therefore, amifostine therapy may increase quality of life in patients with differentiated thyroid cancer after radioiodine treatment.
AB - BACKGROUND AND PURPOSE: Salivary gland impairment following high-dose radioiodine treatment is well recognized. Since differentiated thyroid cancer has a good prognosis, reduction of long-term side effects is important. This study investigates the radioprotective effects of amifostine in salivary glands of rabbits receiving high-dose radioiodine therapy so as to obtain deeper insight in changes on the cellular and ultrastructural level. MATERIAL AND METHODS: A total of 20 rabbits were investigated. High-dose radioiodine therapy applying 1 GBq (131)I was performed in 16 animals. Eight of these 16 animals received 200 mg/m(2) body surface amifostine prior to high-dose radioiodine therapy. Four additional rabbits served as controls, two receiving amifostine, the other two no treatment at all. Subsequently, salivary glands (submandibular and parotid glands, respectively) of all animals were examined by light and transmission electron microscopy. RESULTS: Parenchymal damage of both parotid and submandibular glands, specially acinar structures comprising cell organelles and nuclei, of animals pretreated with amifostine was much less pronounced than in animals without amifostine pretreatment. CONCLUSION: The results indicate that parenchymal damage in salivary glands induced by high-dose radioiodine therapy can significantly be reduced by amifostine. Therefore, amifostine therapy may increase quality of life in patients with differentiated thyroid cancer after radioiodine treatment.
M3 - SCORING: Zeitschriftenaufsatz
VL - 181
SP - 237
EP - 245
JO - STRAHLENTHER ONKOL
JF - STRAHLENTHER ONKOL
SN - 0179-7158
IS - 4
M1 - 4
ER -
